sales@reportocean.com (Bussiness Sales)
+18882123539 (Us - Toll Free)
+919997112116 (Rest Of World)
Prosthetic Heart Valve Market by Product (Mechanical Heart Valve, Tissue Heart Valve (Stented Tissue Heart Valve, and Stentless Tissue Heart Valve), and Transcatheter Heart Valve) - Global Opportunity Analysis and Industry Forecast, 2017-2023

Prosthetic Heart Valve Market by Product (Mechanical Heart Valve, Tissue...

Home / Categories / Healthcare
Prosthetic Heart Valve Market by Product (Mechanical Heart Valve, Tissue Heart Valve (Stented Tissue Heart Valve, and Stentless Tissue Heart Valve), and Transcatheter Heart Valve) - Global Opportunity Analysis and Industry Forecast, 2017-2023
Prosthetic Heart Valve Market by...
Report Code
RO1/113/1184

Publish Date
01/May/2017

Pages
250
PRICE
$ 1800/-
This is a single user license, allowing one specific user access to the product. The product is a PDF.
$ 2350/-
This is a 1-5 user license, allowing up to five users have access to the product. The product is a PDF.
$ 2850/-
This is an enterprise license, allowing all employees within your organization access to the product. The product is a PDF..
CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS FOR STAKEHOLDERS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. KEY FINDINGS OF THE STUDY

2.2. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.2.2.1. Competitive intelligence of companies and their strategies

3.2.3. Market share analysis, 2016

3.3. MARKET DYNAMICS

3.3.1. Drivers

3.3.1.1. Rise in number of patients suffering from structural heart diseases
3.3.1.2. Technological advancements in heart valve replacement devices
3.3.1.3. Growth in demand for minimally invasive procedures
3.3.1.4. Increase in number of TAVR Centers

3.3.2. Restraints

3.3.2.1. High cost and risk associated with the treatment procedures
3.3.2.2. Stringent approval process for prosthetic heart valves

3.3.3. Opportunities

3.3.3.1. Lucrative opportunities in emerging economies
3.3.3.2. Use of transcatheter heart valves for new indications

3.3.4. Impact Analysis

3.4. GOVERNMENT REGULATIONS
3.5. REIMBURSEMENT SCENARIO
3.6. CLINICAL TRIALS

CHAPTER 4 PROSTHETIC HEART VALVE MARKET, BY PRODUCT

4.1. OVERVIEW

4.1.1. Key market trends
4.1.2. Key growth factors and opportunities
4.1.3. Market size and forecast

4.2. MECHANICAL HEART VALVES

4.2.1. Key market trends
4.2.2. Market size and forecast

4.3. TISSUE HEART VALVES

4.3.1. Stented tissue heart valve
4.3.2. Stentless tissue heart valve
4.3.3. Key market trends
4.3.4. Market size and forecast

4.4. TRANSCATHETER HEART VALVES

4.4.1. Key market trends
4.4.2. Market size and forecast

CHAPTER 5 PROSTHETIC HEART VALVE MARKET, BY REGION

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. NORTH AMERICA

5.2.1. Key market trends
5.2.2. Key growth factors and opportunities
5.2.3. Market size and forecast
5.2.4. U.S.
5.2.5. Canada
5.2.6. Mexico

5.3. EUROPE

5.3.1. Key market trends
5.3.2. Key growth factors and opportunities
5.3.3. Market size and forecast
5.3.4. Germany
5.3.5. France
5.3.6. UK
5.3.7. Italy
5.3.8. Spain
5.3.9. The Netherlands
5.3.10. Belgium
5.3.11. Switzerland
5.3.12. Russia
5.3.13. Denmark
5.3.14. Austria
5.3.15. Norway
5.3.16. Poland
5.3.17. Sweden
5.3.18. Rest of Europe

5.4. ASIA-PACIFIC

5.4.1. Key market trends
5.4.2. Key growth factors and opportunities
5.4.3. Market size and forecast
5.4.4. Japan
5.4.5. China
5.4.6. India
5.4.7. Australia
5.4.8. Malaysia
5.4.9. Republic of Korea
5.4.10. New Zealand
5.4.11. Singapore
5.4.12. Thailand
5.4.13. Vietnam
5.4.14. Taiwan
5.4.15. Indonesia
5.4.16. Rest of Asia-Pacific market size and forecast

5.5. LAMEA

5.5.1. Key market trends
5.5.2. Key growth factors and opportunities
5.5.3. Market size and forecast
5.5.4. Brazil
5.5.5. South Africa
5.5.6. Saudi Arabia
5.5.7. United Arab Emirates (UAE)
5.5.8. Libya
5.5.9. Algeria
5.5.10. Kenya
5.5.11. Kuwait
5.5.12. Jordan
5.5.13. Sudan
5.5.14. Morocco
5.5.15. Israel
5.5.16. Zimbabwe
5.5.17. Mauritius
5.5.18. Oman
5.5.19. Argentina
5.5.20. Iran
5.5.21. Iraq
5.5.22. Rest of LAMEA

CHAPTER 6 COMPANY PROFILES

6.1 ABBOTT LABORATORIES

6.1.1 Company Overview
6.1.2 Company Snapshot
6.1.3 Operating Business Segments
6.1.4 Business Performance
6.1.5 Key Strategic Moves & Developments

6.2 BOSTON SCIENTIFIC CORPORATION

6.2.1 Company Overview
6.2.2 Company Snapshot
6.2.3 Operating Business Segments
6.2.4 Business Performance
6.2.5 Key Strategic Moves & Developments

6.3 CRYOLIFE, INC.

6.3.1 Company Overview
6.3.2 Company Snapshot
6.3.3 Operating Business Segments
6.3.4 Business Performance
6.3.5 Key Strategic Moves & Developments

6.4 DIRECT FLOW MEDICAL, INC.

6.4.1 Company Overview
6.4.2 Company Snapshot
6.4.3 Operating Business Segments
6.4.4 Key Strategic Moves & Developments

6.5 EDWARDS LIFESCIENCES CORPORATION

6.5.1 Company Overview
6.5.2 Company Snapshot
6.5.3 Operating Business Segments
6.5.4 Business Performance
6.5.5 Key Strategic Moves & Developments

6.6 JENAVALVE TECHNOLOGY, INC.

6.6.1 Company Overview
6.6.2 Company Snapshot
6.6.3 Operating Business Segments
6.6.4 Key Strategic Moves & Developments

6.7 LIVANOVA PLC

6.7.1 Company Overview
6.7.2 Company Snapshot
6.7.3 Operating Business Segments
6.7.4 Business Performance
6.7.5 Key Strategic Moves & Developments

6.8 MEDICAL TECHNOLOGY EST.

6.8.1 Company Overview
6.8.2 Company Snapshot
6.8.3 Operating Business Segments
6.8.4 Key Strategic Moves & Developments

6.9 MEDTRONIC PLC

6.9.1 Company Overview
6.9.2 Company Snapshot
6.9.3 Operating Business Segments
6.9.4 Business Performance
6.9.5 Key Strategic Moves & Developments

6.10 MICRO INTERVENTIONAL DEVICES, INC.

6.10.1 Company Overview
6.10.2 Company Snapshot
6.10.3 Operating Business Segments
6.10.4 Key Strategic Moves & Developments

OUR CLIENTS

500 N Michigan Ave, Suite 600, Chicago, Illinois 60611, UNITED STATES
+18882123539
sales@reportocean.com